

SYMPOSIUM, "Immunotherapy for Cancer, Current Status and Future Prospects"

At the NRG Semi-Annual Meeting –Atlanta, Georgia, January 21, 2016

Program Chair – Samir N. Khleif, MD – GRU Cancer Center

Presentation Agenda

Time	Topic	Speaker
7:00 am	Registration	
8:00 am	Welcome - Program Chair	
8:05-8:45 am	SESSION I: <i>Immunology 101</i> - Moderator: Ronald D. Alvarez, MD	
8:05-8:30 am	<i>Innate Immunity</i>	Santhakumar Manicassamy, PhD
8:30-8:55 am	<i>Adaptive Immunity</i>	Esteban Celis, MD, PhD
8:55-9:20 am	<i>Overview of Cancer Immunology/Immunotherapy</i>	Samir N. Khleif, MD
9:20-10:40 am	SESSION II: <i>Therapeutic Approaches</i> - Moderator: Harry D. Bear, MD, PhD	
9:20-9:40 am	<i>Cancer Vaccines</i>	Dimitry Zamarin, MD, PhD
9:40-10:00 am	<i>T-Cell Therapy</i>	Janos L. Tanyi, MD, PhD
10:00-10:20 am	<i>Check Point Inhibitors</i>	Elad Sharon, MD
10:20-10:35 am	Questions & Answers	
10:35-10:50 am	Break	
10:50 am-12:20 pm	SESSION III: <i>Future Directions I</i> - Moderator: Samir N. Khleif, MD	
10:50-11:10 am	<i>What is coming 1: Immune Agonists</i>	Brendan Curti, MD
11:10-11:30 am	<i>What is coming 1: Other Immune Modulating Agents</i>	Paulo C. Rodriguez, PhD
11:30-11:50 am	<i>Immune Biomarkers Integration</i>	Lisa H. Butterfield, PhD
11:50-12:10 pm	<i>Alternative Immunotherapy Clinical Trial Design</i>	Richard Simon, PhD
12:10-12:20 pm	Questions & Answers	
12:20-12:30 pm	YIA Presentation	Leslie M. Randall, MD
12:30-1:15 pm	Lunch Break (45 mins)	
1:15-2:35 pm	SESSION IV: <i>Future Directions II</i> - Moderator: Mark Einstein, MD	
1:15-1:35 pm	<i>Combination Immune Therapies</i>	John Janik, MD
1:35-1:55 pm	<i>Combination Immunotherapy with Chemo Therapy</i>	James W. Hodge, PhD
1:55-2:15 pm	<i>Combination Immunotherapy with Radiation Therapy</i>	Marka Critenden, MD, PhD
2:15-2:35 pm	<i>Regulatory Consideration in Clinical Trials</i>	Raj Puri, MD, PhD
2:35-2:55 pm	Questions & Answers	

PROGRAM DESCRIPTION

The winter 2016 GOG Foundation, Inc. Symposium is titled *“Immunotherapy for Cancer, Current Status and Future Prospects,”* with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, and other MDs engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, and other interested Allied Health professionals. The speakers will focus their presentations on the mechanism by which cancer escapes the immune system. Presentations will also be focused on current and future strategies developing immunotherapies that address such mechanisms for good clinical outcomes.

LEARNING OBJECTIVES

1. Recognize basic principles of immunology, both innate and adaptive, especially learn about the principles of T-cell biology and understand the function of different phenotypes of the cells.
2. Examine the interaction between the immune system and cancer cells and the effect of the tumor micro-environment on the immune system.
3. Identify tumor antigenicity and the different strategies that tumors develop to inhibit the immune system and escape an active immune response against tumor antigens.
4. Examine the current FDA approved immunotherapeutic approaches and agents that are currently in clinical trials, including vaccine, cytokines, and immune checkpoint inhibitors. Understand the basic principles behind the biology of these therapies and their clinical impact.
5. Distinguish novel immunotherapeutic agents that are under development, either in early clinical trial development or will be in clinical trials within the next 2-3 years. Analyze their mechanism of action and their potential in being used in specific conditions.
6. Analyze current and potential strategies in the development of combination immunotherapy, which is the way of the future in the therapy of cancer.
7. Recognize the uniqueness of clinical trial development in immunotherapy, including alternative clinical trial design and integration of specific immune biomarkers.
8. Recognize the specific regulatory consideration in immunotherapeutic developments and the interaction between regulatory agencies and developers and between different companies.

GOG Foundation, Inc. Committee on Educational Activities

Ronald Alvarez, MD (Chair)
University of Alabama School of
Medicine
Birmingham, AL

Neil Horowitz, MD
Brigham and Women’s Hospital
Dana Farber Partners Cancer Care
Boston, MA

Frederick Stehman, MD (Co-Chair)
Indiana University School of Medicine
Indianapolis, IN

William Tew, MD
Memorial Sloan Kettering Cancer
Center
New York, NY

Sarah Bernstein, RN, MS, AOCN
Walter Reed National Military Med Ctr.
Bethesda, MD

Michelle N. Small, BSHA (Staff)
Assoc. Director, Education Programs
& CME Compliance
GOG Foundation, Inc.

John Farley, MD
St. Joseph Hospital and Medical Center
Phoenix, AZ

Jill Reese (Staff)
CME Administrator
GOG Foundation, Inc.